"CA-125 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A carbohydrate antigen that occurs in tumors of the ovary as well as in breast, kidney, and gastrointestinal tract tumors and normal tissue. While it is tumor-associated, it is not tumor-specific and may have a protective function against particles and infectious agents at mucosal surfaces.
| Descriptor ID |
D018394
|
| MeSH Number(s) |
D12.776.395.560.631.050 D23.050.285.050.225 D23.050.550.325.225 D23.101.140.075.225
|
| Concept/Terms |
CA-125 Antigen- CA-125 Antigen
- Antigen, CA-125
- Antigen CA-125
- Antigen CA 125
- Mucin-16
- Mucin 16
- CA 125 Antigen
- Antigen, CA 125
|
Below are MeSH descriptors whose meaning is more general than "CA-125 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Mucoproteins [D12.776.395.560]
- Mucins [D12.776.395.560.631]
- CA-125 Antigen [D12.776.395.560.631.050]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Neoplasm [D23.050.285]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.285.050]
- CA-125 Antigen [D23.050.285.050.225]
- Epitopes [D23.050.550]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.550.325]
- CA-125 Antigen [D23.050.550.325.225]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Antigens, Tumor-Associated, Carbohydrate [D23.101.140.075]
- CA-125 Antigen [D23.101.140.075.225]
Below are MeSH descriptors whose meaning is more specific than "CA-125 Antigen".
This graph shows the total number of publications written about "CA-125 Antigen" by people in this website by year, and whether "CA-125 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2008 | 2 | 3 | 5 |
| 2010 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CA-125 Antigen" by people in Profiles.
-
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 Dec 01; 40(34):3965-3974.
-
Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018 02; 148(2):275-280.
-
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol. 2018 01; 148(1):49-55.
-
Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Oncotarget. 2016 Feb 02; 7(5):5943-56.
-
MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget. 2015 Aug 07; 6(22):19118-31.
-
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
-
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
-
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009 Jan; 112(1):55-9.
-
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6.
-
CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecol Oncol. 2008 Nov; 111(2):233-6.